Miao Yuchun, Zhang Yi, Lim Pek S, Kanjanapan Yada, Mori Trevor A, Croft Kevin D, Earl John, Lee Sze Y, McKenzie Katja U S, Hu Lexian, Whitworth Judith A
High Blood Pressure Research Unit, John Curtin School of Medical Research, Australian National University, Canberra, Australia.
Am J Hypertens. 2007 Mar;20(3):304-10. doi: 10.1016/j.amjhyper.2006.08.007.
To investigate the effect of folic acid on the increased pressure in rats treated with either adrenocorticotropic hormone (ACTH) or dexamethasone (Dex), and to further investigate the role of tetrahydrobiopterin (BH(4)) in any effect of folic acid by comparing the effect of BH(4) with that of folic acid in Dex hypertension.
Male Sprague-Dawley (SD) rats were treated with saline, subcutaneous ACTH (0.2 mg/kg/d) or Dex (10 microg/rat/d). Folic acid (0.04 g/L drinking) or BH(4) (10 mg/kg/d intraperitoneally) was started before (prevention) and during (reversal) glucocorticoid treatment.
Saline, BH(4), vehicle for BH(4), or folic acid alone did not change systolic blood pressure (BP). Systolic BP was increased by ACTH and Dex. Folic acid, but not BH(4), prevented the development of hypertension caused by ACTH and Dex treatment. The ACTH and Dex hypertension were partially reversed by folic acid. The BH(4) increased plasma total biopterin concentrations. The Dex decreased plasma NOx concentrations but had no effect on plasma biopterin concentrations. The ACTH and Dex increased plasma F(2)-isoprostane concentrations and decreased serum homocysteine concentrations compared with control but had no effect on serum folate concentrations. Folic acid increased serum folate concentrations compared with control but had no effect on homocysteine concentrations.
Folic acid prevented and partially reversed both ACTH and Dex hypertension in rats without modifying the increase in plasma F(2)-isoprostane concentrations. Given that BH(4) failed to prevent ACTH or Dex hypertension, folic acid is unlikely to be acting through increased BH(4) production. The precise mechanism for the BP-lowering effect of folic acid in this model of hypertension remains to be determined.
研究叶酸对用促肾上腺皮质激素(ACTH)或地塞米松(Dex)处理的大鼠血压升高的影响,并通过比较四氢生物蝶呤(BH₄)与叶酸在Dex高血压中的作用,进一步研究BH₄在叶酸任何作用中的角色。
雄性Sprague-Dawley(SD)大鼠用生理盐水、皮下注射ACTH(0.2mg/kg/d)或Dex(10μg/大鼠/d)处理。在糖皮质激素治疗前(预防)和治疗期间(逆转)开始给予叶酸(0.04g/L饮水)或BH₄(10mg/kg/d腹腔注射)。
生理盐水、BH₄、BH₄的溶剂或单独的叶酸均未改变收缩压(BP)。ACTH和Dex使收缩压升高。叶酸而非BH₄可预防ACTH和Dex治疗所致高血压的发生。ACTH和Dex高血压可被叶酸部分逆转。BH₄可增加血浆总生物蝶呤浓度。Dex可降低血浆NOx浓度,但对血浆生物蝶呤浓度无影响。与对照组相比,ACTH和Dex可增加血浆F₂-异前列腺素浓度并降低血清同型半胱氨酸浓度,但对血清叶酸浓度无影响。与对照组相比,叶酸可增加血清叶酸浓度,但对同型半胱氨酸浓度无影响。
叶酸可预防并部分逆转大鼠的ACTH和Dex高血压,而不改变血浆F₂-异前列腺素浓度的升高。鉴于BH₄未能预防ACTH或Dex高血压,叶酸不太可能通过增加BH₄生成发挥作用。在该高血压模型中,叶酸降压作用的确切机制仍有待确定。